Core Insights - On November 11, Asia-Pacific Pharmaceutical Co., Ltd. saw a stock increase of 1.68% with a trading volume of 1.127 billion yuan [1] - The company reported a financing buy-in amount of 83.81 million yuan and a net financing buy of 1.10 million yuan on the same day [1][2] - As of November 11, the total financing and securities lending balance for the company was 291 million yuan, which is 4.61% of its market capitalization [1] Financing Summary - The financing buy-in for Asia-Pacific Pharmaceutical on November 11 was 83.81 million yuan, with a current financing balance of 291 million yuan, indicating a high level compared to the past year [1] - The financing balance exceeds the 90th percentile level over the past year, indicating a strong position in the market [1] Securities Lending Summary - On November 11, there were no shares repaid or sold in the securities lending market, with a total lending balance of 0.00 yuan, also indicating a high level compared to the past year [1] Company Overview - Asia-Pacific Pharmaceutical Co., Ltd. was established on December 31, 2001, and listed on March 16, 2010 [1] - The company specializes in pharmaceutical manufacturing, including the research, production, and sales of chemical preparations and raw materials [1] - The revenue composition includes 56.49% from antibiotic preparations, 42.84% from non-antibiotic preparations, and 0.67% from other sources [1] Financial Performance - As of September 30, the number of shareholders increased to 91,500, a rise of 66% compared to the previous period [2] - The average number of circulating shares per person decreased by 39.76% to 8,152 shares [2] - For the period from January to September 2025, the company reported a revenue of 22.8 million yuan, a decrease of 25.59% year-on-year, while the net profit attributable to the parent company was 97.20 million yuan, a significant increase of 2909.49% [2] Dividend Information - Since its A-share listing, Asia-Pacific Pharmaceutical has distributed a total of 186 million yuan in dividends, with no dividends paid in the last three years [3]

融资方面，亚太药业当日融资买入376.29万元。当前融资余额1.56亿元，占流通市值的2.78%，融资余 额超过近一年70%分位水平，处于较高位。 分红方面，亚太药业A股上市后累计派现1.86亿元。近三年，累计派现0.00元。 融券方面，亚太药业10月16日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 责任编辑：小浪快报 资料显示，浙江亚太药业股份有限公司位于浙江省绍兴滨海新城沥海镇南滨西路36号，成立日期2001年 12月31日，上市日期2010年3月16日，公司主营业务涉及医药制造业务,包括化学制剂、化学原料药的研 发、生产和销售。主营业务收入构成为：抗生素类制剂56.49%，非抗生素类制剂42.84%，其他(补 充)0.67%。 10月16日，亚太药业涨10.06%，成交额1.40亿元。两融数据显示，当日亚太药业获融资买入额376.29万 元，融资偿还352.40万元，融资净买入23.89万元。截至10月16日，亚太药业融资融券余额合计1.56亿 元。 截至6月30日，亚太药业股东户数5.51 ...

资料显示，浙江亚太药业股份有限公司位于浙江省绍兴滨海新城沥海镇南滨西路36号，成立日期2001年 12月31日，上市日期2010年3月16日，公司主营业务涉及医药制造业务,包括化学制剂、化学原料药的研 发、生产和销售。主营业务收入构成为：抗生素类制剂56.49%，非抗生素类制剂42.84%，其他(补 充)0.67%。 截至6月30日，亚太药业股东户数5.51万，较上期减少9.36%；人均流通股13532股，较上期增加 11.23%。2025年1月-6月，亚太药业实现营业收入1.52亿元，同比减少31.48%；归母净利润1.05亿元，同 比增长1820.97%。 9月17日，亚太药业跌2.41%，成交额2.56亿元。两融数据显示，当日亚太药业获融资买入额1585.92万 元，融资偿还2059.13万元，融资净买入-473.21万元。截至9月17日，亚太药业融资融券余额合计1.89亿 元。 融资方面，亚太药业当日融资买入1585.92万元。当前融资余额1.89亿元，占流通市值的4.17%，融资余 额超过近一年80%分位水平，处于高位。 融券方面，亚太药业9月17日融券偿还0.00股，融券卖出0.00股，按当日收盘 ...